Apoptosis

Bullous Pemphigoid Drug Pipeline Research Report 2023: Comprehensive Insights on 5+ Companies and 5+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Friday, November 10, 2023

The "Bullous Pemphigoid - Pipeline Insight, 2023" report offers comprehensive insights into the pipeline landscape for Bullous Pemphigoid, a skin disorder.

Key Points: 
  • The "Bullous Pemphigoid - Pipeline Insight, 2023" report offers comprehensive insights into the pipeline landscape for Bullous Pemphigoid, a skin disorder.
  • It covers information about more than 5 companies and over 5 pipeline drugs related to Bullous Pemphigoid.
  • Furthermore, the report offers a comprehensive overview of the current status and growth prospects within the Bullous Pemphigoid pipeline landscape.
  • Overall, this report offers a comprehensive and detailed analysis of the Bullous Pemphigoid pipeline landscape, providing valuable insights into the current status and future prospects of potential treatments for this skin disorder.

A unique approach to cancer treatment: Piazza and his pharmacy team bring a new approach to cancer research at Auburn University

Retrieved on: 
Friday, December 1, 2023

Piazza joined the Harrison College of Pharmacy (HCOP) in 2021 as the W.W. Walker Professor and head of the Department of Drug Discovery and Development.

Key Points: 
  • Piazza joined the Harrison College of Pharmacy (HCOP) in 2021 as the W.W. Walker Professor and head of the Department of Drug Discovery and Development.
  • Along with his administrative responsibilities, Piazza continues his groundbreaking research as director of the newly created Cancer Research Center at HCOP.
  • Piazza is optimistic that their lead compound, ADT-1004, is an attractive drug candidate inching closer and closer to clinical trials.
  • Piazza is excited about what can be accomplished on The Plains to be a beacon of hope in the battle to fight cancer.

Montefiore Einstein Comprehensive Cancer Center Awarded FDA Grant for Clinical Trial on Experimental AML/MDS Treatment

Retrieved on: 
Tuesday, November 28, 2023

BRONX, N.Y., Nov. 28, 2023 /PRNewswire/ -- Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)—two related blood diseases that disproportionally strike older adults—are notoriously difficult to treat and associated with high relapse rates. Although new therapies have improved survival, treatment options remain limited, and the prognosis for the 50% of people who experience disease relapse remains poor.

Key Points: 
  • Researchers at the National Cancer Institute-designated Montefiore Einstein Comprehensive Cancer Center (MECCC) were recently awarded a four-year, $2.6 million grant from the U.S. Food and Drug Administration (FDA) to conduct an innovative phase 1 clinical trial of a new drug for patients with relapsed and treatment-resistant forms of AML and MDS.
  • It is one of only 10 grants issued this year by the FDA through its Office of Orphan Products Development.
  • If the researchers find evidence that the experimental treatment has clinical activity, they will expand the study to a phase 2 trial to further assess the treatment's effectiveness.
  • The co-principal investigator of the clinical trial is Naval Daver, M.D., at the MD Anderson Cancer Center.

Cancer therapy shows promise against tuberculosis

Retrieved on: 
Thursday, November 16, 2023

SAN ANTONIO, Nov. 16, 2023 /PRNewswire/ -- A promising new cancer therapy also appears extremely potent against one of the world's most devastating infectious diseases: tuberculosis (TB).

Key Points: 
  • SAN ANTONIO, Nov. 16, 2023 /PRNewswire/ -- A promising new cancer therapy also appears extremely potent against one of the world's most devastating infectious diseases: tuberculosis (TB).
  • - Larry Schlesinger, MD
    Scientists at Texas Biomedical Research Institute (Texas Biomed) found the therapy dramatically reduces TB growth, even for bacteria that are drug-resistant.
  • The therapy evaluated in this study combines two molecules – one is already FDA-approved for cancer patients, and the other is in Phase 1/2 clinical trials for cancer.
  • That's the power of a host-directed therapy targeting the human's immune response versus trying to attack the pathogen directly."

Propanc Biopharma Confirms PRP Enhances Chemosensitivity and Alters Tumor Microenvironment of Pancreatic Tumor Cells

Retrieved on: 
Tuesday, November 7, 2023

Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that PRP enhances the sensitivity of resistant pancreatic tumor cells to standard chemotherapy treatment and alters the tumor microenvironment by decreasing the fibrotic tissue and its malignancy (ability to spread into surrounding tissues).

Key Points: 
  • Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that PRP enhances the sensitivity of resistant pancreatic tumor cells to standard chemotherapy treatment and alters the tumor microenvironment by decreasing the fibrotic tissue and its malignancy (ability to spread into surrounding tissues).
  • Various methods, including apoptosis (programmed cell death) and viability analysis, live/dead assays, and RT-qPCR (real time quantification of gene expression) analyses confirmed PRP enhances the sensitivity of pancreatic tumor cells to standard chemotherapy treatment and decreases expression of genes related to chemoresistance.
  • A synergistic ratio of 1:6 inhibits growth of most tumor cells.
  • Orphan Drug Designation status of PRP has been granted from the US Food and Drug Administration (FDA) for treatment of pancreatic cancer.

Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC)

Retrieved on: 
Friday, November 3, 2023

REDWOOD CITY, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced data from three immuno-oncology pipeline programs at the 38th Annual Meeting of SITC taking place November 1 - 5, 2023 at the San Diego Convention Center in San Diego, CA. Preclinical data presented support differentiated mechanisms of its next-generation immunotherapies potentially enabling the antitumor immune activation in more cancer patients and enhanced treatment outcomes.

Key Points: 
  • Preclinical data presented support differentiated mechanisms of its next-generation immunotherapies potentially enabling the antitumor immune activation in more cancer patients and enhanced treatment outcomes.
  • CCR8 is a chemokine receptor predominantly expressed by tumor infiltrating Tregs that suppress the body’s natural anti-cancer immune response.
  • Targeting CCR8 is a promising potential therapeutic strategy designed to deplete Tregs, reshape the tumor microenvironment and enhance anti-tumor immune response.
  • Data presented compare mechanistic data for LOQTORZI™ to commercially available anti-PD-1 monoclonal antibodies and demonstrate higher expression of key immune system biomarkers with LOQTORZI™.

Gracell Biotechnologies to Present Data Highlighting Preclinical Efficacy of SMART CART™ Against Solid Tumors at Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Retrieved on: 
Tuesday, October 31, 2023

SAN DIEGO and SUZHOU, China and SHANGHAI, China, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (“Gracell” or the “Company”, NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune disease, announced today preclinical data from the Company’s SMART CART™* technology for solid tumors will be presented as a poster at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, taking place November 1-5, 2023, in San Diego and online.

Key Points: 
  • “Gracell has long been dedicated to unlocking the tremendous potential of CAR-T therapy against solid tumors in our pursuit of transformative cell therapies.
  • We are thrilled to present the encouraging preclinical data from SMART CART, our next-generation solid tumor technology,” said Dr. Lianjun Shen, Gracell’s Senior Vice President, Head of Research & Development.
  • “Immunosuppressive tumor microenvironment is a known challenge that limits CAR-T cell proliferation and persistence, and, ultimately, its effectiveness against solid tumors.
  • We believe our research to be presented at SITC demonstrates SMART CART’s improved resistance to TME and superior in vitro and in vivo preclinical efficacy.

Junshi Biosciences Presents 11 Clinical Trials of Toripalimab at the ESMO Congress 2023

Retrieved on: 
Friday, October 27, 2023

At the ESMO Congress 2023, Junshi Bioscience showcased a total of 11 clinical trials involving the groundbreaking immune-oncology drug, toripalimab (anti-PD-1 monoclonal antibody), in the forms of 1 late-breaking abstract, 2 proffered paper oral presentations, and 8 posters.

Key Points: 
  • At the ESMO Congress 2023, Junshi Bioscience showcased a total of 11 clinical trials involving the groundbreaking immune-oncology drug, toripalimab (anti-PD-1 monoclonal antibody), in the forms of 1 late-breaking abstract, 2 proffered paper oral presentations, and 8 posters.
  • “This year’s ESMO Congress highlighted the most recent results from 11 clinical studies conducted with our core product, toripalimab,” said Dr. Jianjun ZOU, Global Research and Development President of Junshi Biosciences.
  • Study findings were unveiled for the first time during a proffered paper session at the ESMO Congress.
  • In terms of safety, toripalimab combined with chemotherapy has a manageable safety profile and no new safety signals were identified.

Can Fite: Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal; Robust anti-Cancer Effect & Molecular Mechanism of Action

Retrieved on: 
Monday, October 30, 2023

The article includes a summary on the robust inhibition of pancreatic carcinoma growth, both in vitro and in vivo and a definitive description of the molecular mechanism of action.

Key Points: 
  • The article includes a summary on the robust inhibition of pancreatic carcinoma growth, both in vitro and in vivo and a definitive description of the molecular mechanism of action.
  • This mechanism is highly important since pancreatic carcinoma cells are resistant to the chemotherapy.
  • “We are very much encouraged by the excellent data in the pre-clinical studies demonstrating the impressive anti-cancer effect of Namodenoson against pancreatic carcinoma,” stated Dr. Fishman, Can-Fite’s Chief Scientific Officer and Executive Chairman.
  • “We plan to start treating patients very shortly and hope that Namodenoson, with its positive safety and efficacy profile, will prolong life for pancreatic cancer patients.”

Pulsed Field Ablation (PFA) Market to Surge at a Stunning 40% CAGR: Revolutionizing Cardiac Ablation and Beyond - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 24, 2023

The Pulsed Field Ablation (PFA) market, a rapidly expanding segment within the cardiac ablation sector, is set to witness robust growth with a projected Compound Annual Growth Rate (CAGR) of approximately 40% during the forecast period of 2023-2035.

Key Points: 
  • The Pulsed Field Ablation (PFA) market, a rapidly expanding segment within the cardiac ablation sector, is set to witness robust growth with a projected Compound Annual Growth Rate (CAGR) of approximately 40% during the forecast period of 2023-2035.
  • However, conventional ablation methods primarily rely on thermal energy, which can lead to tissue overheating and post-procedural pain.
  • Enter pulsed field ablation (PFA), a game-changing approach harnessing high-voltage electrical pulses delivered in short bursts.
  • The Pulsed Field Ablation Market: Distribution by Therapeutic Area, Product Components, Application Areas, Source of Ablation, and Key Geographical Regions report for 2023-2035 provides a comprehensive overview of this rapidly evolving medical devices segment.